메뉴 건너뛰기




Volumn 21, Issue 27, 2014, Pages 3188-3210

The dopamine D2 and adenosine A2A receptors: Past, present and future trends for the treatment of parkinson's disease

Author keywords

Bivalent ligand; Dopamine; G protein coupled receptor; Levodopa; Non dopaminergic drug; Parkinson's disease

Indexed keywords

'PARKIN'; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; APO TRIHEX; BELLADONNA ALKALOID; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE MESILATE; BIPERIDEN; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXTROPROPOXYPHENE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ENTACAPONE; FLEXON; LEVODOPA; LEVOMEPROMAZINE; MONOAMINE OXIDASE B INHIBITOR; NORGESIC; ORFENACE; ORPHENADRINE; ORPHENADRINE CITRATE; PARSIDAN; PROCYCLIDINE; PROFENAMINE; RASAGILINE; SAFINAMIDE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ADENOSINE; ADENOSINE A2A RECEPTOR; DOPAMINE 2 RECEPTOR;

EID: 84906093608     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/1389200215666140217110716     Document Type: Article
Times cited : (39)

References (240)
  • 2
    • 33745919520 scopus 로고    scopus 로고
    • Epidemiology of parkinson's disease
    • de Lau, L.M.L.; Breteler, M.M.B. Epidemiology of Parkinson's disease. Lancet Neurol., 2006, 5(6), 525-535.
    • (2006) Lancet Neurol. , vol.5 , Issue.6 , pp. 525-535
    • De Lau, L.M.L.1    Breteler, M.M.B.2
  • 3
    • 0037417254 scopus 로고    scopus 로고
    • Alzheimer's disease and parkinson's disease
    • Nussbaum, R.L.; Ellis, C.E. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med., 2003, 348, 1356-1364.
    • (2003) N. Engl. J. Med. , vol.348 , pp. 1356-1364
    • Nussbaum, R.L.1    Ellis, C.E.2
  • 4
    • 2542596183 scopus 로고    scopus 로고
    • Parkinson's disease
    • Samii, A.; Nutt, J.G.; Ransom, B.R. Parkinson's disease. Lancet, 2004, 363, 1783-1793.
    • (2004) Lancet , vol.363 , pp. 1783-1793
    • Samii, A.1    Nutt, J.G.2    Ransom, B.R.3
  • 8
    • 0034658015 scopus 로고    scopus 로고
    • Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes
    • Scheife, R.T.; Schumock, G.T.; Burstein, A.; Gottwald, M.D.; Luer, M.S. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am. J. Health Syst. Pharm., 2000, 57, 953-962.
    • (2000) Am. J. Health Syst. Pharm. , vol.57 , pp. 953-962
    • Scheife, R.T.1    Schumock, G.T.2    Burstein, A.3    Gottwald, M.D.4    Luer, M.S.5
  • 11
    • 35048860925 scopus 로고    scopus 로고
    • Management of Parkinson disease: Current treatments, recent advances, and future development
    • Lo, K.; Leung, K.; Shek, A. Management of Parkinson disease: current treatments, recent advances, and future development. Formulary, 2007, 42, 529-544.
    • (2007) Formulary , vol.42 , pp. 529-544
    • Lo, K.1    Leung, K.2    Shek, A.3
  • 12
    • 84865735047 scopus 로고    scopus 로고
    • Medication management of parkinson's disease: Early versus advanced stages
    • Tsai, S.-C.; Yuan, R.-Y. Medication Management of Parkinson's Disease: Early versus Advanced Stages. J. Exp. Clin. Med., 2012, 4(4), 209-214.
    • (2012) J. Exp. Clin. Med. , vol.4 , Issue.4 , pp. 209-214
    • Tsai, S.-C.1    Yuan, R.-Y.2
  • 13
    • 80053898301 scopus 로고    scopus 로고
    • Available and emerging treatments for parkinson's disease: A review
    • Hickey, P.; Stacy, M. Available and emerging treatments for Parkinson's disease: a review. Drug Des. Devel. Ther., 2011, 5, 241-254.
    • (2011) Drug Des. Devel. Ther. , vol.5 , pp. 241-254
    • Hickey, P.1    Stacy, M.2
  • 15
    • 0026005169 scopus 로고
    • N-methyl-d-aspartate antagonists in the treatment of parkinson's disease
    • Greenamyre, J.; O'Brien, C.F. N-methyl-d-aspartate antagonists in the treatment of parkinson's disease. Arch. Neurol., 1991, 48(9), 977-981.
    • (1991) Arch. Neurol. , vol.48 , Issue.9 , pp. 977-981
    • Greenamyre, J.1    O'Brien, C.F.2
  • 17
    • 73449139510 scopus 로고    scopus 로고
    • Novel investigational adenosine A2A receptor antagonists for Parkinson's disease
    • Pinna, A. Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin. Inv. Drug., 2009, 18(11), 1619-1631.
    • (2009) Expert Opin. Inv. Drug. , vol.18 , Issue.11 , pp. 1619-1631
    • Pinna, A.1
  • 18
    • 84859560679 scopus 로고    scopus 로고
    • Therapeutic potential of A2 and A3 adenosine receptor: A review of novel patented ligands
    • Federico, S.; Spalluto, G. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands. Expert Opin. Ther. Pat., 2012, 22, 369-390.
    • (2012) Expert Opin. Ther. Pat. , vol.22 , pp. 369-390
    • Federico, S.1    Spalluto, G.2
  • 19
    • 84863687148 scopus 로고    scopus 로고
    • A2A receptor antagonism and dyskinesia in Parkinson's disease
    • Morelli, M.; Blandini, F.; Simola, N.; Hauser, R.A. A2A receptor antagonism and dyskinesia in Parkinson's disease. Parkinson's Dis., 2012, 489853-489861.
    • (2012) Parkinson's Dis. , pp. 489853-489861
    • Morelli, M.1    Blandini, F.2    Simola, N.3    Hauser, R.A.4
  • 20
    • 80054959849 scopus 로고    scopus 로고
    • Adenosine A2A receptor antagonists and parkinson's disease
    • Shook, B.C.; Jackson, P.F. Adenosine A2A Receptor Antagonists and Parkinson's Disease. ACS Chem. Neurosci., 2011, 2, 555-567.
    • (2011) ACS Chem. Neurosci. , vol.2 , pp. 555-567
    • Shook, B.C.1    Jackson, P.F.2
  • 21
    • 79952918806 scopus 로고    scopus 로고
    • Novel therapy in Parkinson's disease: Adenosine A2A receptor antagonists
    • Szaboo, N.; Kincses, Z.T.; Veecsei, L., Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists. Expert Opin. Drug Metab. Toxicol., 2011, 7, 441-455.
    • (2011) Expert Opin Drug Metab. Toxicol. , vol.7 , pp. 441-455
    • Szaboo, N.1    Kincses, Z.T.2    Veecsei, L.3
  • 22
    • 1442302324 scopus 로고    scopus 로고
    • Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease
    • Chen, L.W.; Yung, K.K.L.; Chan, Y.S. Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease. Curr. Drug Targets, 2004, 5, 197-206.
    • (2004) Curr. Drug Targets , vol.5 , pp. 197-206
    • Chen, L.W.1    Yung, K.K.L.2    Chan, Y.S.3
  • 24
    • 80055002811 scopus 로고    scopus 로고
    • Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
    • Armentero, M.T.; Pinna, A.; Ferre, S.; Lanciego, J.L.; Mueller, C.E.; Franco, R. Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther., 2011, 132, 280-299.
    • (2011) Pharmacol. Ther. , vol.132 , pp. 280-299
    • Armentero, M.T.1    Pinna, A.2    Ferre, S.3    Lanciego, J.L.4    Mueller, C.E.5    Franco, R.6
  • 26
    • 84859735330 scopus 로고    scopus 로고
    • Gene therapy for parkinson's disease
    • Denyer, R.; Douglas, M.R. Gene therapy for Parkinson's disease. Parkinsons Dis., 2012, 2012, 757305.
    • (2012) Parkinsons Dis. , vol.2012 , pp. 757305
    • Denyer, R.1    Douglas, M.R.2
  • 27
    • 84860213812 scopus 로고    scopus 로고
    • Challenges for gene therapy of CNS disorders and implications for parkinson's disease therapies
    • Broadstock, M.; Yanez-Munoz, R.J. Challenges for Gene Therapy of CNS Disorders and Implications for Parkinson's Disease Therapies. Hum. Gene Ther., 2012, 23, 340-343.
    • (2012) Hum. Gene Ther. , vol.23 , pp. 340-343
    • Broadstock, M.1    Yanez-Munoz, R.J.2
  • 28
    • 80052876242 scopus 로고    scopus 로고
    • The current status of gene therapy for parkinson's disease
    • Muramastsu, S.-I. The current status of gene therapy for Parkinson's disease. Ann. Neurosci., 2010, 17, 92-95.
    • (2010) Ann. Neurosci. , vol.17 , pp. 92-95
    • Muramastsu, S.-I.1
  • 29
    • 84870153310 scopus 로고    scopus 로고
    • Recent progress in gene therapy for parkinson's disease
    • Nakata, Y.; Yasuda, T.; Mochizuki, H. Recent progress in gene therapy for Parkinson's disease. Curr. Mol. Med., 2012, 12, 1311-1318.
    • (2012) Curr. Mol. Med. , vol.12 , pp. 1311-1318
    • Nakata, Y.1    Yasuda, T.2    Mochizuki, H.3
  • 30
    • 80054804774 scopus 로고    scopus 로고
    • An update on gene therapy in parkinson's disease
    • Witt, J.; Marks, W.J., Jr. An Update on Gene Therapy in Parkinson's Disease. Curr. Neurol. Neurosci. Rep., 2011, 11, 362-370.
    • (2011) Curr. Neurol. Neurosci. Rep. , vol.11 , pp. 362-370
    • Witt, J.1    Marks Jr., W.J.2
  • 31
    • 84870885663 scopus 로고    scopus 로고
    • AAV2-neurturin (CERE-120) for parkinson's disease
    • Hickey, P.; Stacy, M. AAV2-neurturin (CERE-120) for Parkinson's disease. Expert Opin. Biol. Ther., 2013, 13(1), 137-145.
    • (2013) Expert Opin. Biol. Ther. , vol.13 , Issue.1 , pp. 137-145
    • Hickey, P.1    Stacy, M.2
  • 34
    • 41949110690 scopus 로고    scopus 로고
    • Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, phase i trial
    • Marks, W.J., Jr.; Ostrem, J.L.; Verhagen, L.; Starr, P.A.; Larson, P.S.; Bakay, R.A.; Taylor, R.; Cahn-Weiner, D.A.; Stoessl, A.J.; Olanow, C.W.; Bartus, R.T. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol., 2008, 7, 400-408.
    • (2008) Lancet Neurol. , vol.7 , pp. 400-408
    • Marks Jr., W.J.1    Ostrem, J.L.2    Verhagen, L.3    Starr, P.A.4    Larson, P.S.5    Bakay, R.A.6    Taylor, R.7    Cahn-Weiner, D.A.8    Stoessl, A.J.9    Olanow, C.W.10    Bartus, R.T.11
  • 35
    • 23744497262 scopus 로고    scopus 로고
    • Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models
    • Lee, B.; Lee, H.; Nam, Y.R.; Oh, J.H.; Cho, Y.H.; Chang, J.W. Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Ther., 2005, 12, 1215-1222.
    • (2005) Gene Ther. , vol.12 , pp. 1215-1222
    • Lee, B.1    Lee, H.2    Nam, Y.R.3    Oh, J.H.4    Cho, Y.H.5    Chang, J.W.6
  • 44
    • 0034328925 scopus 로고    scopus 로고
    • Gene therapy: Trials and tribulations
    • Somia, N.; Verma, I.M. Gene therapy: trials and tribulations. Nat. Rev. Genet., 2000, 1, 91-99.
    • (2000) Nat. Rev. Genet. , vol.1 , pp. 91-99
    • Somia, N.1    Verma, I.M.2
  • 46
    • 34249750111 scopus 로고    scopus 로고
    • Jean-Martin Charcot (1825-1893): Pathologist who shaped modern neurology
    • Tan, S.Y.; Shigaki, D. Jean-Martin Charcot (1825-1893): pathologist who shaped modern neurology. Singapore Med. J., 2007, 48, 383-384.
    • (2007) Singapore Med. J. , vol.48 , pp. 383-384
    • Tan, S.Y.1    Shigaki, D.2
  • 47
    • 0027868194 scopus 로고
    • Jean-Martin Charcot (1825-1893): His life and his legacy
    • Dubb, A. Jean-Martin Charcot (1825-1893): his life and his legacy. Adler. Mus. Bull., 1993, 19, 19-24.
    • (1993) Adler. Mus. Bull. , vol.19 , pp. 19-24
    • Dubb, A.1
  • 48
    • 84876058527 scopus 로고    scopus 로고
    • The history of Parkinson's disease: Early clinical descriptions and neurological therapies
    • Goetz, C.G., The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb. Perspect. Med., 2011, 1, a008862.
    • (2011) Cold Spring Harb Perspect. Med. , vol.1
    • Goetz, C.G.1
  • 49
    • 0036933810 scopus 로고    scopus 로고
    • Lesions as therapy: Surgical intervention in Parkinson's disease prior to L-dopa
    • Clower, W.T. Lesions as therapy: surgical intervention in Parkinson's disease prior to L-dopa. J. Hist. Neurosci., 2002, 11, 375-391.
    • (2002) J. Hist. Neurosci. , vol.11 , pp. 375-391
    • Clower, W.T.1
  • 50
    • 0023235687 scopus 로고
    • Whatever happened to stereotactic surgery
    • Gildenberg, P.L. Whatever happened to stereotactic surgery? Neurosurgery, 1987, 20, 983-987.
    • (1987) Neurosurgery , vol.20 , pp. 983-987
    • Gildenberg, P.L.1
  • 51
    • 0031770369 scopus 로고    scopus 로고
    • Stereotactic surgery \-The past and the future
    • Gildenberg, P.L. Stereotactic surgery \-The past and the future. Stereotact. Funct. Neurosurg., 1998, 70, 57-70.
    • (1998) Stereotact. Funct. Neurosurg. , vol.70 , pp. 57-70
    • Gildenberg, P.L.1
  • 52
    • 0033986486 scopus 로고    scopus 로고
    • Stereotactic surgery: What is past is prologue
    • Kelly, P.J. Stereotactic surgery: what is past is prologue. Neurosurgery, 2000, 46, 16-27.
    • (2000) Neurosurgery , vol.46 , pp. 16-27
    • Kelly, P.J.1
  • 53
    • 0034050835 scopus 로고    scopus 로고
    • Thalamic, pallidal, or subthalamic surgery for Parkinson's disease
    • Krack, P.; Poepping, M.; Weinert, D.; Schrader, B.; Deuschl, G. Thalamic, pallidal, or subthalamic surgery for Parkinson's disease? J. Neurol., 2000, 247 II122-134.
    • (2000) J. Neurol. , vol.247 , pp. 122-134
    • Krack, P.1    Poepping, M.2    Weinert, D.3    Schrader, B.4    Deuschl, G.5
  • 54
    • 84906088600 scopus 로고    scopus 로고
    • Adapted from the following figure on
    • Adapted from the following figure on http://biomed.brown.edu/ Courses/BI108/BI108-2003-Groups/Deep-Brain-Stimulation/ images/brainslice1.gif.
  • 55
    • 67649225086 scopus 로고    scopus 로고
    • Deep brain stimulation-surgery for movement disorders and Parkinson's disease
    • Frost, E.A.M.; Osborn, I. Deep brain stimulation-surgery for movement disorders and Parkinson's disease. Int. Anesthesiol Clin., 2009, 47, 57-68.
    • (2009) Int. Anesthesiol Clin. , vol.47 , pp. 57-68
    • Frost, E.A.M.1    Osborn, I.2
  • 56
    • 84863409621 scopus 로고    scopus 로고
    • Efficacy and safety of deep brain stimulation as an adjunct to pharmacotherapy for the treatment of Parkinson disease
    • Sharma, A.; Szeto, K.; Desilets, A.R. Efficacy and safety of deep brain stimulation as an adjunct to pharmacotherapy for the treatment of Parkinson disease. Ann. Pharmacother., 2012, 46, 248-254.
    • (2012) Ann. Pharmacother. , vol.46 , pp. 248-254
    • Sharma, A.1    Szeto, K.2    Desilets, A.R.3
  • 57
    • 0036924327 scopus 로고    scopus 로고
    • Anonymous, Surgical treatment for Parkinson's disease: Deep brain surgery
    • Anonymous, Surgical treatment for Parkinson's disease: deep brain surgery. Movement Disord., 2002, 17, 128-147.
    • (2002) Movement Disord. , vol.17 , pp. 128-147
  • 58
    • 1942422564 scopus 로고    scopus 로고
    • Deep brain stimulation surgery for Parkinson's disease: Mechanisms and consequences
    • Lozano, A.M.; Mahant, N. Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences. Parkinsonism Relat. Disord., 2004, 10 49-57.
    • (2004) Parkinsonism Relat. Disord. , vol.10 , pp. 49-57
    • Lozano, A.M.1    Mahant, N.2
  • 60
    • 77950623416 scopus 로고    scopus 로고
    • Cell-based therapeutic approaches for Parkinson's disease: Progress and perspectives
    • Anisimov, S.V. Cell-based therapeutic approaches for Parkinson's disease: progress and perspectives. Rev. Neurosci., 2009, 20, 347-381.
    • (2009) Rev. Neurosci. , vol.20 , pp. 347-381
    • Anisimov, S.V.1
  • 61
    • 72949111183 scopus 로고    scopus 로고
    • Dopaminergic transplantation for parkinson's disease: Current status and future prospects
    • Olanow, C.W.; Kordower, J.H.; Lang, A.E.; Obeso, J.A. Dopaminergic transplantation for parkinson's disease: current status and future prospects. Ann. Neurol., 2009, 66, 591-596.
    • (2009) Ann. Neurol. , vol.66 , pp. 591-596
    • Olanow, C.W.1    Kordower, J.H.2    Lang, A.E.3    Obeso, J.A.4
  • 62
    • 42649086036 scopus 로고    scopus 로고
    • Stem cells and Parkinson's disease: Toward a treatment, not a cure
    • Svendsen, C. Stem cells and Parkinson's disease: toward a treatment, not a cure. Cell Stem Cell, 2008, 2, 412-413.
    • (2008) Cell Stem Cell , vol.2 , pp. 412-413
    • Svendsen, C.1
  • 63
    • 34248177735 scopus 로고    scopus 로고
    • Current advances in the treatment of parkinson's disease with stem cells
    • Trzaska, K.A.; Rameshwar, P. Current advances in the treatment of Parkinson's disease with stem cells. Curr. Neurovasc. Res., 2007, 4, 99-109.
    • (2007) Curr. Neurovasc. Res. , vol.4 , pp. 99-109
    • Trzaska, K.A.1    Rameshwar, P.2
  • 68
    • 84880357897 scopus 로고    scopus 로고
    • Development of M1 mACHR allosteric and bitopic ligands: Prospective therapeutics for the treatment of cognitive deficits
    • Davie, B.J.; Christopoulos, A.; Scammells, P.J. Development of M1 mAChR Allosteric and Bitopic Ligands: Prospective Therapeutics for the Treatment of Cognitive Deficits. ACS Chem. Neurosci., 2013, 4, 1026-1048.
    • (2013) ACS Chem. Neurosci. , vol.4 , pp. 1026-1048
    • Davie, B.J.1    Christopoulos, A.2    Scammells, P.J.3
  • 69
    • 18344413707 scopus 로고    scopus 로고
    • Anonymous, Management of Parkinson's disease: An evidencebased review
    • Anonymous, Management of Parkinson's disease: an evidencebased review. Movement Disord., 2002, 17, 1-166.
    • (2002) Movement Disord. , vol.17 , pp. 1-166
  • 70
    • 24144502098 scopus 로고    scopus 로고
    • Alternatives to levodopa in the initial treatment of early Parkinson's disease
    • Lees, A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging, 2005, 22, 731-740.
    • (2005) Drugs Aging , vol.22 , pp. 731-740
    • Lees, A.1
  • 71
    • 0036589897 scopus 로고    scopus 로고
    • Dopamine miracle: From brain homogenate to dopamine replacement
    • Hornykiewicz, O. Dopamine miracle: from brain homogenate to dopamine replacement. Movement Disord., 2002, 17, 501-508.
    • (2002) Movement Disord. , vol.17 , pp. 501-508
    • Hornykiewicz, O.1
  • 72
    • 4243605003 scopus 로고
    • Synthesis of d,l-3,4-Dihydroxyphenylalanine
    • Funk, C. Synthesis of d,l-3,4-Dihydroxyphenylalanine. J. Chem. Soc., Trans., 1911, 99, 554-557.
    • (1911) J. Chem. Soc., Trans. , vol.99 , pp. 554-557
    • Funk, C.1
  • 73
    • 0001145589 scopus 로고
    • Dioxyphenylalanin, eine neue aminosaeure aus vicia faba
    • Guggenheim, M. Dioxyphenylalanin, eine neue Aminosaeure aus Vicia faba. Hoppe-Seyler's Zeitschr. Physiol. Chem., 1913(88), 276-284.
    • (1913) Hoppe-Seyler's Zeitschr. Physiol. Chem. , Issue.88 , pp. 276-284
    • Guggenheim, M.1
  • 74
    • 0002595892 scopus 로고
    • Enzymic destruction of ldihydroxyphenylalanine (dopa) by the kidney
    • Holtz, P.; Heise, R.; Ludtke, K. Enzymic destruction of ldihydroxyphenylalanine (dopa) by the kidney. Arch. Exp. Pathol. Pharmakol., 1938, 191, 87-118.
    • (1938) Arch. Exp. Pathol. Pharmakol. , vol.191 , pp. 87-118
    • Holtz, P.1    Heise, R.2    Ludtke, K.3
  • 75
    • 0000285068 scopus 로고
    • Dopa decarboxylase
    • Holtz, P. Dopa decarboxylase. Naturwissenschaften, 1939, 27, 724-725.
    • (1939) Naturwissenschaften , vol.27 , pp. 724-725
    • Holtz, P.1
  • 76
    • 0002552282 scopus 로고
    • The specific action of l-dopa decarboxylase
    • Blaschko, H. The specific action of l-dopa decarboxylase. J. Physiol., 1939, 96, 50-51.
    • (1939) J. Physiol. , vol.96 , pp. 50-51
    • Blaschko, H.1
  • 77
    • 0000428532 scopus 로고
    • 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists
    • Carlsson, A.; Lindqvist, M.; Magnusson, T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 1957, 180, 1200.
    • (1957) Nature , vol.180 , pp. 1200
    • Carlsson, A.1    Lindqvist, M.2    Magnusson, T.3
  • 78
    • 0001058813 scopus 로고
    • Serotonin release as a mechanism of reserpine action
    • Pletscher, A.; Shore, P.A.; Brodie, B.B. Serotonin release as a mechanism of reserpine action. Science, 1955, 122, 374-375.
    • (1955) Science , vol.122 , pp. 374-375
    • Pletscher, A.1    Shore, P.A.2    Brodie, B.B.3
  • 79
    • 0000015266 scopus 로고
    • The occurrence, distribution and physiological role of catecholamines in the nervous system
    • Carlsson, A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev., 1959, 11, 490-493.
    • (1959) Pharmacol. Rev. , vol.11 , pp. 490-493
    • Carlsson, A.1
  • 80
    • 0000424628 scopus 로고
    • Catechol compounds in rat tissues and in brains of different animals
    • Montagu, K.A. Catechol compounds in rat tissues and in brains of different animals. Nature, 1957, 180, 244-245.
    • (1957) Nature , vol.180 , pp. 244-245
    • Montagu, K.A.1
  • 81
    • 0000275068 scopus 로고
    • Intracellular distribution of catecholamines in the brain
    • Weil-Malherbe, H.; Bone, A.D. Intracellular distribution of catecholamines in the brain. Nature, 1957, 180, 1050-1051.
    • (1957) Nature , vol.180 , pp. 1050-1051
    • Weil-Malherbe, H.1    Bone, A.D.2
  • 82
    • 0000022434 scopus 로고
    • Occurrence and distribution of catechol amines in brain
    • Bertler, A.; Rosengren, E. Occurrence and distribution of catechol amines in brain. Acta Physiol. Scand., 1959, 47, 350-361.
    • (1959) Acta Physiol. Scand. , vol.47 , pp. 350-361
    • Bertler, A.1    Rosengren, E.2
  • 83
    • 34250928307 scopus 로고
    • Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain and its relation to diseases of the extrapyramidal system
    • Ehringer, H.; Hornykiewicz, O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain and its relation to diseases of the extrapyramidal system. Klin. Wochenschr., 1960, 38, 1236-1239.
    • (1960) Klin. Wochenschr. , vol.38 , pp. 1236-1239
    • Ehringer, H.1    Hornykiewicz, O.2
  • 84
    • 73049129373 scopus 로고
    • The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia
    • Birkmayer, W.; Hornykiewicz, O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin. Wochenschr., 1961, 73, 787-788.
    • (1961) Wien Klin. Wochenschr. , vol.73 , pp. 787-788
    • Birkmayer, W.1    Hornykiewicz, O.2
  • 85
    • 0344018017 scopus 로고
    • The efficacy of l-dopa in Parkinson patients with and without stereotactic brain surgery
    • Umbach, W.; Baumann, D. The efficacy of l-dopa in Parkinson patients with and without stereotactic brain surgery. Arch. Psychiatr. Nervenkr., 1964, 205, 281-292.
    • (1964) Arch. Psychiatr. Nervenkr. , vol.205 , pp. 281-292
    • Umbach, W.1    Baumann, D.2
  • 86
    • 76549151865 scopus 로고
    • Effect of L-dopa on akinesia and other extrapyramidal motor disorders
    • Hirschmann, J.; Mayer, K. Effect of L-dopa on akinesia and other extrapyramidal motor disorders. Deut. Med. Wochenschr., 1964, 89, 1877-1880.
    • (1964) Deut. Med. Wochenschr. , vol.89 , pp. 1877-1880
    • Hirschmann, J.1    Mayer, K.2
  • 88
    • 0344537380 scopus 로고
    • Dopamine metabolism in Parkinsonism
    • Greer, M.; Williams, C.M. Dopamine metabolism in Parkinsonism. Neurology, 1963, 13, 73-76.
    • (1963) Neurology , vol.13 , pp. 73-76
    • Greer, M.1    Williams, C.M.2
  • 89
    • 0014208039 scopus 로고
    • Aromatic amino acids and modification of parkinsonism
    • Cotzias, G.C.; Van, W.M.H.; Schiffer, L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med., 1967, 276, 374-379.
    • (1967) N. Engl. J. Med. , vol.276 , pp. 374-379
    • Cotzias, G.C.1    Van, W.M.H.2    Schiffer, L.M.3
  • 90
    • 0014673226 scopus 로고
    • Modification of Parkinsonism-chronic treatment with L-dopa
    • Cotzias, G.C.; Papavasiliou, P.S.; Gellene, R. Modification of Parkinsonism-chronic treatment with L-dopa. N. Engl. J. Med., 1969, 280, 337-345.
    • (1969) N. Engl. J. Med. , vol.280 , pp. 337-345
    • Cotzias, G.C.1    Papavasiliou, P.S.2    Gellene, R.3
  • 91
    • 0015151902 scopus 로고
    • Treatment of parkinsonism with levodopa Follow-up after 2 years of treatment
    • Lee, J.E.; Sweet, R.D.; McDowell, F.H. Treatment of parkinsonism with levodopa. Follow-up after 2 years of treatment. Ann. Intern. Med., 1971, 75, 703-708.
    • (1971) Ann. Intern. Med. , vol.75 , pp. 703-708
    • Lee, J.E.1    Sweet, R.D.2    McDowell, F.H.3
  • 93
    • 53149145972 scopus 로고    scopus 로고
    • The history of dopamine and levodopa in the treatment of Parkinson's disease
    • Fahn, S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Movement Disord., 2008, 23(S3), 497-508.
    • (2008) Movement Disord. , vol.23 , Issue.S3 , pp. 497-508
    • Fahn, S.1
  • 95
    • 0037176848 scopus 로고    scopus 로고
    • Levodopa strengths and weaknesses
    • Jankovic, J. Levodopa strengths and weaknesses. Neurology, 2002, 58, 19-32.
    • (2002) Neurology , vol.58 , pp. 19-32
    • Jankovic, J.1
  • 96
    • 0023404750 scopus 로고
    • Clinical pharmacokinetics of antiparkinsonian drugs
    • Cedarbaum, J.M. Clinical pharmacokinetics of antiparkinsonian drugs. Clin. Pharmacokinet., 1987, 13, 141-178.
    • (1987) Clin. Pharmacokinet. , vol.13 , pp. 141-178
    • Cedarbaum, J.M.1
  • 97
    • 36849055017 scopus 로고    scopus 로고
    • Monoamine oxidase-b inhibition in the treatment of parkinson's disease
    • Fernandez, H.H.; Chen, J.J. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy, 2007, 27, 174-185.
    • (2007) Pharmacotherapy , vol.27 , pp. 174-185
    • Fernandez, H.H.1    Chen, J.J.2
  • 98
    • 9044227267 scopus 로고
    • Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
    • Lees, A.J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br. Med. J., 1995, 311, 1602-1607.
    • (1995) Br. Med. J. , vol.311 , pp. 1602-1607
    • Lees, A.J.1
  • 99
    • 0036231440 scopus 로고    scopus 로고
    • Impact of sustained deprenyl (selegiline) in levodopatreated parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    • Shoulson, I.; Oakes, D.; Fahn, S.; Lang, A.; Langston, J.W.; LeWitt, P.; Olanow, C.W.; Penney, J.B.; Tanner, C.; Kieburtz, K.; Rudolph, A. Impact of sustained deprenyl (selegiline) in levodopatreated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol., 2002, 51, 604-612.
    • (2002) Ann. Neurol. , vol.51 , pp. 604-612
    • Shoulson, I.1    Oakes, D.2    Fahn, S.3    Lang, A.4    Langston, J.W.5    Lewitt, P.6    Olanow, C.W.7    Penney, J.B.8    Tanner, C.9    Kieburtz, K.10    Rudolph, A.11
  • 101
    • 15844386001 scopus 로고    scopus 로고
    • Rasagiline as an adjunct to levodopa in patients with parkinson's disease and motor fluctuations (largo, lasting effect in adjunct therapy with rasagiline given once daily, study): A randomized, double-blind, parallel-group trial
    • Rascol, O.; Brooks, D.J.; Melamed, E.; Oertel, W.; Poewe, W.; Stocchi, F.; Tolosa, E. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet, 2005, 365, 947-954.
    • (2005) Lancet , vol.365 , pp. 947-954
    • Rascol, O.1    Brooks, D.J.2    Melamed, E.3    Oertel, W.4    Poewe, W.5    Stocchi, F.6    Tolosa, E.7
  • 102
    • 0041633741 scopus 로고    scopus 로고
    • Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase b inhibition
    • Cattaneo, C.; Caccia, C.; Marzo, A.; Maj, R.; Fariello, R.G. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin. Neuropharmacol., 2003, 26, 213-217.
    • (2003) Clin. Neuropharmacol. , vol.26 , pp. 213-217
    • Cattaneo, C.1    Caccia, C.2    Marzo, A.3    Maj, R.4    Fariello, R.G.5
  • 103
    • 33750000049 scopus 로고    scopus 로고
    • Symptom relief in parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond mao-b inhibition
    • Stocchi, F.; Vacca, L.; Grassini, P.; De, P.M.F.; Battaglia, G.; Cattaneo, C.; Fariello, R.G. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology, 2006, 67, 24-29.
    • (2006) Neurology , vol.67 , pp. 24-29
    • Stocchi, F.1    Vacca, L.2    Grassini, P.3    De, P.M.F.4    Battaglia, G.5    Cattaneo, C.6    Fariello, R.G.7
  • 104
    • 77955832709 scopus 로고    scopus 로고
    • Safinamide in the treatment of parkinson's disease
    • Schapira, A.H.V. Safinamide in the treatment of Parkinson's disease. Expert Opin. Pharmacother., 2010, 11, 2261-2268.
    • (2010) Expert Opin. Pharmacother. , vol.11 , pp. 2261-2268
    • Schapira, A.H.V.1
  • 105
    • 84861760612 scopus 로고    scopus 로고
    • Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment
    • Espinoza, S.; Manago, F.; Leo, D.; Sotnikova, T.D.; Gainetdinov, R.R. Role of catechol-O-methyltransferase (COMT)-dependent processes in Parkinson's disease and L-DOPA treatment. CNS Neurol. Disord.: Drug Targets, 2012, 11, 251-263.
    • (2012) CNS Neurol. Disord.: Drug Targets , vol.11 , pp. 251-263
    • Espinoza, S.1    Manago, F.2    Leo, D.3    Sotnikova, T.D.4    Gainetdinov, R.R.5
  • 106
    • 0028137620 scopus 로고
    • Effect of entacapone, a peripherally acting catechol-omethyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with parkinson's disease
    • Merello, M.; Lees, A.J.; Webster, R.; Bovingdon, M.; Gordin, A. Effect of entacapone, a peripherally acting catechol-Omethyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1994, 57, 186-189.
    • (1994) J. Neurol. Neurosurg. Psychiatry , vol.57 , pp. 186-189
    • Merello, M.1    Lees, A.J.2    Webster, R.3    Bovingdon, M.4    Gordin, A.5
  • 107
    • 0031028464 scopus 로고    scopus 로고
    • Tolcapone improves motor function and reduces levodopa requirement in patients with parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial
    • Kurth, M.C.; Adler, C.H.; St, H.M.; Singer, C.; Waters, C.; LeWitt, P.; Chernik, D.A.; Dorflinger, E.E.; Yoo, K. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Neurology, 1997, 48, 81-87.
    • (1997) Neurology , vol.48 , pp. 81-87
    • Kurth, M.C.1    Adler, C.H.2    St, H.M.3    Singer, C.4    Waters, C.5    Lewitt, P.6    Chernik, D.A.7    Dorflinger, E.E.8    Yoo, K.9
  • 108
    • 0028286186 scopus 로고
    • Effect of peripheral catechol-o-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
    • Nutt, J.G.; Woodward, W.R.; Beckner, R.M.; Stone, C.K.; Berggren, K.; Carter, J.H.; Gancher, S.T.; Hammerstad, J.P.; Gordin, A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology, 1994, 44, 913-919.
    • (1994) Neurology , vol.44 , pp. 913-919
    • Nutt, J.G.1    Woodward, W.R.2    Beckner, R.M.3    Stone, C.K.4    Berggren, K.5    Carter, J.H.6    Gancher, S.T.7    Hammerstad, J.P.8    Gordin, A.9
  • 109
    • 33646104205 scopus 로고    scopus 로고
    • Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review)
    • Suchowersky, O.; Gronseth, G.; Perlmutter, J.; Reich, S.; Zesiewicz, T.; Weiner, W.J. Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Neurology, 2006, 66, 976-982.
    • (2006) Neurology , vol.66 , pp. 976-982
    • Suchowersky, O.1    Gronseth, G.2    Perlmutter, J.3    Reich, S.4    Zesiewicz, T.5    Weiner, W.J.6
  • 110
    • 0034871806 scopus 로고    scopus 로고
    • Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP 1012) with selegiline
    • Kupsch, A.; Sautter, J.; Gotz, M.E.; Breithaupt, W.; Schwarz, J.; Youdim, M.B.H.; Riederer, P.; Gerlach, M.; Oertel, W.H. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm., 2001, 108, 985-1009.
    • (2001) J. Neural Transm. , vol.108 , pp. 985-1009
    • Kupsch, A.1    Sautter, J.2    Gotz, M.E.3    Breithaupt, W.4    Schwarz, J.5    Youdim, M.B.H.6    Riederer, P.7    Gerlach, M.8    Oertel, W.H.9
  • 111
    • 2342547676 scopus 로고    scopus 로고
    • Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
    • Blandini, F.; Armentero, M.T.; Fancellu, R.; Blaugrund, E.; Nappi, G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol., 2004, 187, 455-459.
    • (2004) Exp. Neurol. , vol.187 , pp. 455-459
    • Blandini, F.1    Armentero, M.T.2    Fancellu, R.3    Blaugrund, E.4    Nappi, G.5
  • 112
    • 67649116292 scopus 로고    scopus 로고
    • New drug delivery strategies for improved parkinson's disease therapy
    • Di, S.A.; Sozio, P.; Iannitelli, A.; Cerasa, L.S. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin. Drug Del., 2009, 6, 389-404.
    • (2009) Expert Opin. Drug Del. , vol.6 , pp. 389-404
    • Di, S.A.1    Sozio, P.2    Iannitelli, A.3    Cerasa, L.S.4
  • 114
    • 8044229410 scopus 로고    scopus 로고
    • Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: A multicenter 5-year study
    • Block, G.; Liss, C.; Reines, S.; Irr, J.; Nibbelink, D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. Eur. Neurol., 1997, 37, 23-27.
    • (1997) Eur. Neurol. , vol.37 , pp. 23-27
    • Block, G.1    Liss, C.2    Reines, S.3    Irr, J.4    Nibbelink, D.5
  • 115
    • 0141632746 scopus 로고    scopus 로고
    • Clinical strategies to prevent and delay motor complications
    • Barone, P. Clinical strategies to prevent and delay motor complications. Neurology, 2003, 61, 12-16.
    • (2003) Neurology , vol.61 , pp. 12-16
    • Barone, P.1
  • 117
    • 33745386214 scopus 로고    scopus 로고
    • Long-term 24-hour duodenal infusion of levodopa: Outcome and dose requirements
    • Deleu, D.; Hanssens, Y. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology, 2006, 66, 1611-1612.
    • (2006) Neurology , vol.66 , pp. 1611-1612
    • Deleu, D.1    Hanssens, Y.2
  • 118
    • 34648847390 scopus 로고    scopus 로고
    • Continuous dopaminergic stimulation-from theory to clinical practice
    • Antonini, A. Continuous dopaminergic stimulation-from theory to clinical practice. Parkinsonism Relat. Disord., 2007, 13 24-28.
    • (2007) Parkinsonism Relat. Disord. , vol.13 , pp. 24-28
    • Antonini, A.1
  • 120
    • 84875271113 scopus 로고    scopus 로고
    • Extended-release carbidopalevodopa (IPX066) compared with immediate-release carbidopalevodopa in patients with Parkinson's disease and motor fluctuations: A phase 3 randomised, double-blind trial
    • Hauser, R.A.; Hsu, A.; Kell, S.; Espay, A.J.; Sethi, K.; Stacy, M.; Ondo, W.; O'Connell, M.; Gupta, S. Extended-release carbidopalevodopa (IPX066) compared with immediate-release carbidopalevodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol., 2013, 12(4), 346-356.
    • (2013) Lancet Neurol. , vol.12 , Issue.4 , pp. 346-356
    • Hauser, R.A.1    Hsu, A.2    Kell, S.3    Espay, A.J.4    Sethi, K.5    Stacy, M.6    Ondo, W.7    O'Connell, M.8    Gupta, S.9
  • 121
    • 79960696174 scopus 로고    scopus 로고
    • A brief history of levodopa
    • Hornykiewicz, O. A brief history of levodopa. J. Neurol., 2010, 257(2), 249-252.
    • (2010) J. Neurol. , vol.257 , Issue.2 , pp. 249-252
    • Hornykiewicz, O.1
  • 122
    • 65449135642 scopus 로고    scopus 로고
    • Levodopa: Past, present, and future
    • Hauser, R.A. Levodopa: Past, Present, and Future. Eur. Neurol., 2009, 62, 1-8.
    • (2009) Eur. Neurol. , vol.62 , pp. 1-8
    • Hauser, R.A.1
  • 123
    • 0014787409 scopus 로고
    • Newer medical treatment in parkinsonism
    • Schwarz, G.A.; Fahn, S. Newer medical treatment in parkinsonism. Med. Clin. North Am., 1970, 54, 773-785.
    • (1970) Med. Clin. North Am. , vol.54 , pp. 773-785
    • Schwarz, G.A.1    Fahn, S.2
  • 124
    • 41749111396 scopus 로고    scopus 로고
    • Optimizing long-term therapy for parkinson disease: Options for treatment-associated dyskinesia
    • Stacy, M.; Galbreath, A. Optimizing Long-Term Therapy for Parkinson Disease: Options for Treatment-Associated Dyskinesia. Clin. Neuropharmacol., 2008, 31, 120-125.
    • (2008) Clin. Neuropharmacol. , vol.31 , pp. 120-125
    • Stacy, M.1    Galbreath, A.2
  • 125
    • 38549168908 scopus 로고    scopus 로고
    • Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa
    • Hauser, R.A.; Rascol, O.; Korczyn, A.D.; Jon, S.A.; Watts, R.L.; Poewe, W.; De, D.P.P.; Lang, A.E. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disord., 2007, 22, 2409-2417.
    • (2007) Movement Disord. , vol.22 , pp. 2409-2417
    • Hauser, R.A.1    Rascol, O.2    Korczyn, A.D.3    Jon, S.A.4    Watts, R.L.5    Poewe, W.6    De, D.P.P.7    Lang, A.E.8
  • 126
    • 69949085340 scopus 로고    scopus 로고
    • A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
    • Antonini, A.; Tolosa, E.; Mizuno, Y.; Yamamoto, M.; Poewe, W.H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol., 2009, 8, 929-937.
    • (2009) Lancet Neurol. , vol.8 , pp. 929-937
    • Antonini, A.1    Tolosa, E.2    Mizuno, Y.3    Yamamoto, M.4    Poewe, W.H.5
  • 127
    • 0037176885 scopus 로고    scopus 로고
    • Neuroprotection and dopamine agonists
    • Schapira, A.H.V. Neuroprotection and dopamine agonists. Neurology, 2002, 58, 9-18.
    • (2002) Neurology , vol.58 , pp. 9-18
    • Schapira, A.H.V.1
  • 128
    • 0036460167 scopus 로고    scopus 로고
    • Dopamine agonists and neuroprotection in Parkinson's disease
    • Schapira, A.H.V. Dopamine agonists and neuroprotection in Parkinson's disease. Eur. J. Neurol., 2002, 9, 7-14.
    • (2002) Eur. J. Neurol. , vol.9 , pp. 7-14
    • Schapira, A.H.V.1
  • 131
    • 0025298537 scopus 로고
    • Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: A highly potent selective dopamine D1 full agonist
    • Brewster, W.K.; Nichols, D.E.; Riggs, R.M.; Mottola, D.M.; Lovenberg, T.W.; Lewis, M.H.; Mailman, R.B. Trans-10,11-dihydroxy-5,6,6a,7,8,12b- hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J. Med. Chem., 1990, 33, 1756-1764.
    • (1990) J. Med. Chem. , vol.33 , pp. 1756-1764
    • Brewster, W.K.1    Nichols, D.E.2    Riggs, R.M.3    Mottola, D.M.4    Lovenberg, T.W.5    Lewis, M.H.6    Mailman, R.B.7
  • 132
    • 0031003929 scopus 로고    scopus 로고
    • Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist
    • Smith, H.P.; Nichols, D.E.; Mailman, R.B.; Lawler, C.P. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur. J. Pharmacol., 1997, 323, 27-36.
    • (1997) Eur. J. Pharmacol. , vol.323 , pp. 27-36
    • Smith, H.P.1    Nichols, D.E.2    Mailman, R.B.3    Lawler, C.P.4
  • 133
    • 84873167479 scopus 로고    scopus 로고
    • Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease
    • Luthra, P.M.; Kumar, J.B.S. Plausible improvements for selective targeting of dopamine receptors in therapy of Parkinson's disease. Mini-Rev. Med. Chem., 2012, 12, 1556-1564.
    • (2012) Mini-Rev. Med. Chem. , vol.12 , pp. 1556-1564
    • Luthra, P.M.1    Kumar, J.B.S.2
  • 134
    • 0027518471 scopus 로고
    • Subtypes and localization of dopamine receptors in human brain
    • De, K.J. Subtypes and localization of dopamine receptors in human brain. Neurochem. Int., 1993, 22, 83-93.
    • (1993) Neurochem. Int. , vol.22 , pp. 83-93
    • De, K.J.1
  • 135
    • 33745052903 scopus 로고    scopus 로고
    • Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study
    • Barone, P.; Scarzella, L.; Marconi, R.; Antonini, A.; Morgante, L.; Bracco, F.; Zappia, M.; Musch, B. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J. Neurol., 2006, 253, 601-607.
    • (2006) J. Neurol. , vol.253 , pp. 601-607
    • Barone, P.1    Scarzella, L.2    Marconi, R.3    Antonini, A.4    Morgante, L.5    Bracco, F.6    Zappia, M.7    Musch, B.8
  • 136
    • 0030828275 scopus 로고    scopus 로고
    • Antidepressant effects of pramipexole, a novel dopamine receptor agonist
    • Maj, J.; Rogoz, Z.; Skuza, G.; Kolodziejczyk, K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J. Neural Transm., 1997, 104, 525-533.
    • (1997) J. Neural Transm. , vol.104 , pp. 525-533
    • Maj, J.1    Rogoz, Z.2    Skuza, G.3    Kolodziejczyk, K.4
  • 137
    • 33745098959 scopus 로고    scopus 로고
    • D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease
    • Lewis, M.M.; Huang, X.; Nichols, D.E.; Mailman, R.B. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol. Disord.: Drug Targets, 2006, 5, 345-353.
    • (2006) CNS Neurol. Disord.: Drug Targets , vol.5 , pp. 345-353
    • Lewis, M.M.1    Huang, X.2    Nichols, D.E.3    Mailman, R.B.4
  • 138
    • 0034801739 scopus 로고    scopus 로고
    • Choosing dopamine agonists in Parkinson's disease
    • Tan, E.-K.; Jankovic, J. Choosing dopamine agonists in Parkinson's disease. Clin. Neuropharmacol., 2001, 24, 247-253.
    • (2001) Clin. Neuropharmacol. , vol.24 , pp. 247-253
    • Tan, E.-K.1    Jankovic, J.2
  • 139
    • 0141649537 scopus 로고    scopus 로고
    • Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: An evidence-based comparison
    • Inzelberg, R.; Schechtman, E.; Nisipeanu, P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging, 2003, 20, 847-855.
    • (2003) Drugs Aging , vol.20 , pp. 847-855
    • Inzelberg, R.1    Schechtman, E.2    Nisipeanu, P.3
  • 143
    • 0038390136 scopus 로고    scopus 로고
    • Fibrosis associated with dopamine agonist therapy in Parkinson's disease
    • Müller, T.; Fritze, J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin. Neuropharmacol., 2003, 26, 109-111.
    • (2003) Clin. Neuropharmacol. , vol.26 , pp. 109-111
    • Müller, T.1    Fritze, J.2
  • 144
    • 33748522433 scopus 로고    scopus 로고
    • A review of the receptorbinding and pharmacokinetic properties of dopamine agonists
    • Kvernmo, T.; Hartter, S.; Burger, E. A review of the receptorbinding and pharmacokinetic properties of dopamine agonists. Clin. Ther., 2006, 28, 1065-1078.
    • (2006) Clin. Ther. , vol.28 , pp. 1065-1078
    • Kvernmo, T.1    Hartter, S.2    Burger, E.3
  • 146
    • 63149158721 scopus 로고    scopus 로고
    • Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment
    • Luedde, M.; Helmke, B.; Katus, H.A.; Frey, N. Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment. Int. J. Cardiol., 2009, 133, e97-98.
    • (2009) Int. J. Cardiol. , vol.133
    • Luedde, M.1    Helmke, B.2    Katus, H.A.3    Frey, N.4
  • 147
    • 33750079581 scopus 로고    scopus 로고
    • Rotigotine for the treatment of parkinson's disease
    • Morgan, J.C.; Sethi, K.D. Rotigotine for the treatment of Parkinson's disease. Expert Rev. Neurother., 2006, 6, 1275-1282.
    • (2006) Expert Rev. Neurother. , vol.6 , pp. 1275-1282
    • Morgan, J.C.1    Sethi, K.D.2
  • 148
    • 0036490942 scopus 로고    scopus 로고
    • Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery
    • Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Discov., 2002, 1, 198-210.
    • (2002) Nat. Rev. Drug Discov. , vol.1 , pp. 198-210
    • Christopoulos, A.1
  • 149
    • 70350464948 scopus 로고    scopus 로고
    • Allosteric modulators of G protein-coupled receptors: Future therapeutics for complex physiological disorders
    • Wang, L.; Martin, B.; Brenneman, R.; Luttrell, L.M.; Maudsley, S. Allosteric modulators of G protein-coupled receptors: future therapeutics for complex physiological disorders. J. Pharmacol. Exp. Ther., 2009, 331, 340-348.
    • (2009) J. Pharmacol. Exp. Ther. , vol.331 , pp. 340-348
    • Wang, L.1    Martin, B.2    Brenneman, R.3    Luttrell, L.M.4    Maudsley, S.5
  • 150
    • 67650489125 scopus 로고    scopus 로고
    • Orthosteric/allosteric bitopic ligands: Going hybrid at GPCRs
    • Valant, C.; Sexton, P.M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Interv., 2009, 9(3), 125-135.
    • (2009) Mol. Interv. , vol.9 , Issue.3 , pp. 125-135
    • Valant, C.1    Sexton, P.M.2    Christopoulos, A.3
  • 151
    • 84855879360 scopus 로고    scopus 로고
    • The best of both worlds? Bitopic orthosteric/allosteric ligands of G proteincoupled receptors
    • Valant, C.; Lane, J.R.; Sexton, P.M.; Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of G proteincoupled receptors. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 153-178.
    • (2012) Annu. Rev. Pharmacol. Toxicol. , vol.52 , pp. 153-178
    • Valant, C.1    Lane, J.R.2    Sexton, P.M.3    Christopoulos, A.4
  • 152
    • 79957596498 scopus 로고    scopus 로고
    • Design strategies for bivalent ligands targeting GPCRs
    • Shonberg, J.; Scammells, P.J.; Capuano, B. Design Strategies for Bivalent Ligands Targeting GPCRs. ChemMedChem, 2011, 6(6), 963-974.
    • (2011) ChemMedChem , vol.6 , Issue.6 , pp. 963-974
    • Shonberg, J.1    Scammells, P.J.2    Capuano, B.3
  • 153
    • 57349190625 scopus 로고    scopus 로고
    • Bivalent ligands as specific pharmacological tools for g-protein-coupled receptor dimers
    • Berque-Bestel, I.; Lezoulac'h, F.; Jockers, R. Bivalent Ligands as Specific Pharmacological Tools for G-Protein-Coupled Receptor Dimers. Curr. Drug Discovery Technol., 2008, 5(312-318), 312.
    • (2008) Curr. Drug Discovery Technol. , vol.5 , Issue.312-318 , pp. 312
    • Berque-Bestel, I.1    Lezoulac'H, F.2    Jockers, R.3
  • 154
    • 84872048999 scopus 로고    scopus 로고
    • The potential for selective pharmacological therapies through biased receptor signaling
    • Kenakin, T. The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol. Toxicol., 2012, 13, 3.
    • (2012) BMC Pharmacol. Toxicol. , vol.13 , pp. 3
    • Kenakin, T.1
  • 155
    • 84875227396 scopus 로고    scopus 로고
    • Signalling bias in new drug discovery: Detection, quantification and therapeutic impact
    • Kenakin, T.; Christopoulos, A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov., 2013, 12, 205-216.
    • (2013) Nat. Rev. Drug Discov. , vol.12 , pp. 205-216
    • Kenakin, T.1    Christopoulos, A.2
  • 156
    • 58149193205 scopus 로고    scopus 로고
    • Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders
    • Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov., 2009, 8, 41-54.
    • (2009) Nat. Rev. Drug Discov. , vol.8 , pp. 41-54
    • Conn, P.J.1    Christopoulos, A.2    Lindsley, C.W.3
  • 157
    • 84857759143 scopus 로고    scopus 로고
    • The different ways through which specificity works in orthosteric and allosteric drugs
    • Nussinov, R.; Tsai, C.-J. The different ways through which specificity works in orthosteric and allosteric drugs. Curr. Pharm. Des., 2012, 18, 1311-1316.
    • (2012) Curr. Pharm. Des. , vol.18 , pp. 1311-1316
    • Nussinov, R.1    Tsai, C.-J.2
  • 159
    • 27744548649 scopus 로고    scopus 로고
    • The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS
    • Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem., 2005, 43, 239-271.
    • (2005) Prog. Med. Chem. , vol.43 , pp. 239-271
    • Wood, A.1    Armour, D.2
  • 161
    • 84861553696 scopus 로고    scopus 로고
    • Pathophysiology of GPCR homo-and hetero-dimerization: Special emphasis on somatostatin receptors
    • Somvanshi, R.K.; Kumar, U. Pathophysiology of GPCR homo-and hetero-dimerization: special emphasis on somatostatin receptors. Pharmaceuticals, 2012, 5, 417-446.
    • (2012) Pharmaceuticals , vol.5 , pp. 417-446
    • Somvanshi, R.K.1    Kumar, U.2
  • 163
    • 0034616021 scopus 로고    scopus 로고
    • Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
    • Rocheville, M.; Lange, D.C.; Kumar, U.; Patel, S.C.; Patel, R.C.; Patel, Y.C. Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity. Science, 2000, 288, 154-157.
    • (2000) Science , vol.288 , pp. 154-157
    • Rocheville, M.1    Lange, D.C.2    Kumar, U.3    Patel, S.C.4    Patel, R.C.5    Patel, Y.C.6
  • 164
    • 79955878044 scopus 로고    scopus 로고
    • From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes [erratum to document cited in ca135:116529]
    • Portoghese, P.S. From Models to Molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. [Erratum to document cited in CA135:116529]. J. Med. Chem., 2001, 44, 3758.
    • (2001) J. Med. Chem. , vol.44 , pp. 3758
    • Portoghese, P.S.1
  • 165
    • 84857430512 scopus 로고    scopus 로고
    • Homobivalent ligands of the atypical antipsychotic clozapine: Design, synthesis, and pharmacological evaluation
    • McRobb, F.M.; Crosby, I.T.; Yuriev, E.; Lane, J.R.; Capuano, B. Homobivalent ligands of the atypical antipsychotic clozapine: design, synthesis, and pharmacological evaluation. J. Med. Chem., 2012, 55, 1622-1634.
    • (2012) J. Med. Chem. , vol.55 , pp. 1622-1634
    • McRobb, F.M.1    Crosby, I.T.2    Yuriev, E.3    Lane, J.R.4    Capuano, B.5
  • 166
    • 79960172993 scopus 로고    scopus 로고
    • Bivalent dopamine D2 receptor ligands: Synthesis and binding properties
    • Kü hhorn, J.; Hü bner, H.; Gmeiner, P. Bivalent Dopamine D2 Receptor Ligands: Synthesis and Binding Properties. J. Med. Chem., 2011, 54, 4896-4903.
    • (2011) J. Med. Chem. , vol.54 , pp. 4896-4903
    • Kü Hhorn, J.1    Hü Bner, H.2    Gmeiner, P.3
  • 167
    • 34447626644 scopus 로고    scopus 로고
    • GPCR functional selectivity has therapeutic impact
    • Mailman, R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol. Sci., 2007, 28, 390-396.
    • (2007) Trends Pharmacol. Sci. , vol.28 , pp. 390-396
    • Mailman, R.B.1
  • 168
    • 33751162165 scopus 로고    scopus 로고
    • Distinct signaling profiles of -1 and -2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the multidimensionality of efficacy
    • Galandrin, S.; Bouvier, M. Distinct signaling profiles of -1 and -2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the multidimensionality of efficacy. Mol. Pharmacol., 2006, 70, 1575-1584.
    • (2006) Mol. Pharmacol. , vol.70 , pp. 1575-1584
    • Galandrin, S.1    Bouvier, M.2
  • 169
    • 77952354490 scopus 로고    scopus 로고
    • Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery
    • Kenakin, T.; Miller, L.J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev., 2010, 62, 265-304.
    • (2010) Pharmacol. Rev. , vol.62 , pp. 265-304
    • Kenakin, T.1    Miller, L.J.2
  • 170
    • 30444456827 scopus 로고    scopus 로고
    • Design and synthesis of photoaffinity-labeling ligands of the l-prolyl-l-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor
    • Fisher, A.; Mann, A.; Verma, V.; Thomas, N.; Mishra, R.K.; Johnson, R.L. Design and Synthesis of Photoaffinity-Labeling Ligands of the L-Prolyl-L-leucylglycinamide Binding Site Involved in the Allosteric Modulation of the Dopamine Receptor. J. Med. Chem., 2006, 49, 307-317.
    • (2006) J. Med. Chem. , vol.49 , pp. 307-317
    • Fisher, A.1    Mann, A.2    Verma, V.3    Thomas, N.4    Mishra, R.K.5    Johnson, R.L.6
  • 171
    • 0023870799 scopus 로고
    • Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: Evidence for modulation of agonist affinity states in bovine striatal membranes
    • Srivastava, L.K.; Bajwa, S.B.; Johnson, R.L.; Mishra, R.K. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes. J. Neurochem., 1988, 50, 960-968.
    • (1988) J. Neurochem. , vol.50 , pp. 960-968
    • Srivastava, L.K.1    Bajwa, S.B.2    Johnson, R.L.3    Mishra, R.K.4
  • 173
    • 84873480917 scopus 로고    scopus 로고
    • Development of peptidomimetic ligands of Pro-Leu-Gly-NH2 as allosteric modulators of the dopamine D2 receptor
    • Bhagwanth, S.; Mishra, R.K.; Johnson, R.L. Development of peptidomimetic ligands of Pro-Leu-Gly-NH2 as allosteric modulators of the dopamine D2 receptor. Beilstein J. Org. Chem., 2013, 9, 204-214.
    • (2013) Beilstein J. Org. Chem. , vol.9 , pp. 204-214
    • Bhagwanth, S.1    Mishra, R.K.2    Johnson, R.L.3
  • 174
    • 84859885147 scopus 로고    scopus 로고
    • Transformation of Pro-Leu-Gly-NH2 peptidomimetic positive allosteric modulators of the dopamine D2 receptor into negative modulators
    • Bhagwanth, S.; Mishra, S.; Daya, R.; Mah, J.; Mishra, R.K.; Johnson, R.L. Transformation of Pro-Leu-Gly-NH2 Peptidomimetic Positive Allosteric Modulators of the Dopamine D2 Receptor into Negative Modulators. ACS Chem. Neurosci., 2012, 3, 274-284.
    • (2012) ACS Chem. Neurosci. , vol.3 , pp. 274-284
    • Bhagwanth, S.1    Mishra, S.2    Daya, R.3    Mah, J.4    Mishra, R.K.5    Johnson, R.L.6
  • 175
    • 71049142202 scopus 로고    scopus 로고
    • 1,1'-disubstituted ferrocenes as molecular hinges in mono-and bivalent dopamine receptor ligands
    • Huber, D.; Hubner, H.; Gmeiner, P. 1,1'-Disubstituted Ferrocenes as Molecular Hinges in Mono-and Bivalent Dopamine Receptor Ligands. J. Med. Chem., 2009, 52, 6860-6870.
    • (2009) J. Med. Chem. , vol.52 , pp. 6860-6870
    • Huber, D.1    Hubner, H.2    Gmeiner, P.3
  • 176
    • 84855186679 scopus 로고    scopus 로고
    • Bivalent molecular probes for dopamine D2-like receptors
    • Huber, D.; Loeber, S.; Huebner, H.; Gmeiner, P. Bivalent molecular probes for dopamine D2-like receptors. Bioorg. Med. Chem., 2012, 20, 455-466.
    • (2012) Bioorg. Med. Chem. , vol.20 , pp. 455-466
    • Huber, D.1    Loeber, S.2    Huebner, H.3    Gmeiner, P.4
  • 178
    • 84871255186 scopus 로고    scopus 로고
    • Novel bivalent ligands for D2/D3 dopamine receptors: Significant cooperative gain in d2 affinity and potency
    • Gogoi, S.; Biswas, S.; Modi, G.; Antonio, T.; Reith, M.E.A.; Dutta, A.K. Novel Bivalent Ligands for D2/D3 Dopamine Receptors: Significant Cooperative Gain in D2 Affinity and Potency. ACS Med. Chem. Lett., 2012, 3(12), 991-996.
    • (2012) ACS Med. Chem. Lett. , vol.3 , Issue.12 , pp. 991-996
    • Gogoi, S.1    Biswas, S.2    Modi, G.3    Antonio, T.4    Reith, M.E.A.5    Dutta, A.K.6
  • 183
    • 3042630989 scopus 로고    scopus 로고
    • Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: Evidence for induction of ligandspecific receptor states
    • Gay, E.A.; Urban, J.D.; Nichols, D.E.; Oxford, G.S.; Mailman, R.B. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: Evidence for induction of ligandspecific receptor states. Mol. Pharmacol., 2004, 66, 97-105.
    • (2004) Mol. Pharmacol. , vol.66 , pp. 97-105
    • Gay, E.A.1    Urban, J.D.2    Nichols, D.E.3    Oxford, G.S.4    Mailman, R.B.5
  • 185
    • 0042474326 scopus 로고    scopus 로고
    • Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTPlesioned primate model of Parkinson's disease
    • Savola, J.-M.; Hill, M.; Engstrom, M.; Merivuori, H.; Wurster, S.; McGuire, S.G.; Fox, S.H.; Crossman, A.R.; Brotchie, J.M. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTPlesioned primate model of Parkinson's disease. Movement Disord., 2003, 18, 872-883.
    • (2003) Movement Disord. , vol.18 , pp. 872-883
    • Savola, J.-M.1    Hill, M.2    Engstrom, M.3    Merivuori, H.4    Wurster, S.5    McGuire, S.G.6    Fox, S.H.7    Crossman, A.R.8    Brotchie, J.M.9
  • 187
    • 77955380256 scopus 로고    scopus 로고
    • Maladaptive striatal plasticity in LDOPA-induced dyskinesia
    • Cenci, M.A.; Konradi, C. Maladaptive striatal plasticity in LDOPA-induced dyskinesia. Prog. Brain Res., 2010, 183, 209-233.
    • (2010) Prog. Brain Res. , vol.183 , pp. 209-233
    • Cenci, M.A.1    Konradi, C.2
  • 188
    • 67649847847 scopus 로고    scopus 로고
    • Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: Effects on motor behavior and striatal nuclear signaling
    • Rylander, D.; Recchia, A.; Mela, F.; Dekundy, A.; Danysz, W.; Cenci, M.A. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther., 2009, 330, 227-235.
    • (2009) J. Pharmacol. Exp. Ther. , vol.330 , pp. 227-235
    • Rylander, D.1    Recchia, A.2    Mela, F.3    Dekundy, A.4    Danysz, W.5    Cenci, M.A.6
  • 189
    • 82955189290 scopus 로고    scopus 로고
    • Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
    • Sgambato-Faure, V.; Cenci, M.A. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog. Neurobiol. (Oxford, U. K.), 2012, 96, 69-86.
    • (2012) Prog. Neurobiol. (Oxford, U. K.) , vol.96 , pp. 69-86
    • Sgambato-Faure, V.1    Cenci, M.A.2
  • 192
    • 69549126673 scopus 로고    scopus 로고
    • Serotonin and Parkinson's disease: On movement, mood, and madness
    • Fox, S.H.; Chuang, R.; Brotchie, J.M. Serotonin and Parkinson's disease: On movement, mood, and madness. Movement Disord., 2009, 24, 1255-1266.
    • (2009) Movement Disord. , vol.24 , pp. 1255-1266
    • Fox, S.H.1    Chuang, R.2    Brotchie, J.M.3
  • 193
    • 33847757879 scopus 로고    scopus 로고
    • Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebocontrolled trial
    • Goetz, C.G.; Damier, P.; Hicking, C.; Laska, E.; Muller, T.; Olanow, C.W.; Rascol, O.; Russ, H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebocontrolled trial. Movement Disord., 2007, 22, 179-186.
    • (2007) Movement Disord. , vol.22 , pp. 179-186
    • Goetz, C.G.1    Damier, P.2    Hicking, C.3    Laska, E.4    Muller, T.5    Olanow, C.W.6    Rascol, O.7    Russ, H.8
  • 194
    • 78049251350 scopus 로고    scopus 로고
    • Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats
    • Tani, Y.; Ogata, A.; Koyama, M.; Inoue, T. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats. Eur. J. Pharmacol., 2010, 649, 218-223.
    • (2010) Eur. J. Pharmacol. , vol.649 , pp. 218-223
    • Tani, Y.1    Ogata, A.2    Koyama, M.3    Inoue, T.4
  • 195
    • 51449123001 scopus 로고    scopus 로고
    • Non-dopaminergic treatments in development for Parkinson's disease
    • Fox, S.H.; Brotchie, J.M.; Lang, A.E. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol., 2008, 7, 927-938.
    • (2008) Lancet Neurol. , vol.7 , pp. 927-938
    • Fox, S.H.1    Brotchie, J.M.2    Lang, A.E.3
  • 196
    • 0035209620 scopus 로고    scopus 로고
    • International union of pharmacology XXV nomenclature and classification of adenosine receptors
    • Fredholm, B.B.; IJzerman, A.P.; Jacobson, K.A.; Klotz, K.-N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacol. Rev., 2001, 53(4), 527-552.
    • (2001) Pharmacol. Rev. , vol.53 , Issue.4 , pp. 527-552
    • Fredholm, B.B.1    Ijzerman, A.P.2    Jacobson, K.A.3    Klotz, K.-N.4    Linden, J.5
  • 197
    • 79952033865 scopus 로고    scopus 로고
    • International union of basic and clinical pharmacology LXXXI. Nomenclature and classification of adenosine receptors-an update
    • Fredholm, B.B.; Ijzerman, A.P.; Jacobson, K.A.; Linden, J.; Mueller, C.E. International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol. Rev., 2011, 63, 1-34.
    • (2011) Pharmacol. Rev. , vol.63 , pp. 1-34
    • Fredholm, B.B.1    Ijzerman, A.P.2    Jacobson, K.A.3    Linden, J.4    Mueller, C.E.5
  • 198
    • 79952027612 scopus 로고    scopus 로고
    • Recent developments in adenosine receptor ligands and their potential as novel drugs
    • Mueller, C.E.; Jacobson, K.A. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim. Biophys. Acta, Biomembr., 2011, 1808, 1290-1308.
    • (2011) Biochim. Biophys. Acta, Biomembr. , vol.1808 , pp. 1290-1308
    • Mueller, C.E.1    Jacobson, K.A.2
  • 199
    • 14544288232 scopus 로고    scopus 로고
    • Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
    • Xu, K.; Bastia, E.; Schwarzschild, M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol. Ther., 2005, 105, 267-310.
    • (2005) Pharmacol. Ther. , vol.105 , pp. 267-310
    • Xu, K.1    Bastia, E.2    Schwarzschild, M.3
  • 201
    • 47349112609 scopus 로고    scopus 로고
    • Adenosine A2A receptor antagonists and Parkinson's disease: State of the art and future directions
    • Simola, N.; Morelli, M.; Pinna, A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr. Pharm. Des., 2008, 14, 1475-1489.
    • (2008) Curr. Pharm. Des. , vol.14 , pp. 1475-1489
    • Simola, N.1    Morelli, M.2    Pinna, A.3
  • 202
    • 0035195117 scopus 로고    scopus 로고
    • Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in Parkinson's disease
    • Morelli, M.; Wardas, J. Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotoxic. Res., 2001, 3, 545-556.
    • (2001) Neurotoxic. Res. , vol.3 , pp. 545-556
    • Morelli, M.1    Wardas, J.2
  • 203
    • 0035318509 scopus 로고    scopus 로고
    • Oglimerization of G-protein-coupled transmitter receptors
    • Bouvier, M., Oglimerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci., 2001, 2, 274-286.
    • (2001) Nat Rev. Neurosci. , vol.2 , pp. 274-286
    • Bouvier, M.1
  • 206
    • 84858226578 scopus 로고    scopus 로고
    • Crosstalk within gpcr heteromers in schizophrenia and parkinson's disease: Physical or just functional
    • Guixa-Gonzalez, R.; Bruno, A.; Marti-Solano, M.; Selent, J. Crosstalk within GPCR heteromers in schizophrenia and Parkinson's disease: physical or just functional? Curr. Med. Chem., 2012, 19, 1119-1134.
    • (2012) Curr. Med. Chem. , vol.19 , pp. 1119-1134
    • Guixa-Gonzalez, R.1    Bruno, A.2    Marti-Solano, M.3    Selent, J.4
  • 209
    • 84880762491 scopus 로고    scopus 로고
    • Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385
    • Jörg, M.; Agostino, M.; Yuriev, E.; Mak, F.S.; Miller, N.D.; White, J.; Scammells, P.J.; Capuano, B. Synthesis, molecular structure, NMR spectroscopic and computational analysis of a selective adenosine A2A antagonist, ZM 241385. Struct. Chem., 2013, 24, 1241-1251.
    • (2013) Struct. Chem. , vol.24 , pp. 1241-1251
    • Jörg, M.1    Agostino, M.2    Yuriev, E.3    Mak, F.S.4    Miller, N.D.5    White, J.6    Scammells, P.J.7    Capuano, B.8
  • 210
    • 84877584576 scopus 로고    scopus 로고
    • Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space
    • Jörg, M.; Shonberg, J.; Mak, F.S.; Miller, N.D.; Yuriev, E.; Scammells, P.J.; Capuano, B. Novel adenosine A2A receptor ligands: A synthetic, functional and computational investigation of selected literature adenosine A2A receptor antagonists for extending into extracellular space. Bioorg. Med. Chem. Lett., 2013, 23, 3427-3433.
    • (2013) Bioorg. Med. Chem. Lett. , vol.23 , pp. 3427-3433
    • Jörg, M.1    Shonberg, J.2    Mak, F.S.3    Miller, N.D.4    Yuriev, E.5    Scammells, P.J.6    Capuano, B.7
  • 211
    • 84871806184 scopus 로고    scopus 로고
    • Stabilised G protein-coupled receptors in structure-based drug design: A case study with adenosine A2A receptor
    • Andrews, S.P.; Tehan, B. Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor. Med. Chem. Commun., 2013, 4, 52-67.
    • (2013) Med. Chem. Commun. , vol.4 , pp. 52-67
    • Andrews, S.P.1    Tehan, B.2
  • 215
    • 80155142267 scopus 로고    scopus 로고
    • Future treatments for parkinson's disease: Surfing the pd pipeline
    • Hauser, R.A. Future Treatments for Parkinson's Disease: Surfing the PD Pipeline. Int. J. Neurosci., 2011, 121, 53-62.
    • (2011) Int. J. Neurosci. , vol.121 , pp. 53-62
    • Hauser, R.A.1
  • 216
    • 84878952850 scopus 로고    scopus 로고
    • Istradefylline: First global approval
    • Dungo, R.; Deeks, E.D. Istradefylline: first global approval. Drugs, 2013, 73, 875-882.
    • (2013) Drugs , vol.73 , pp. 875-882
    • Dungo, R.1    Deeks, E.D.2
  • 217
    • 0033038568 scopus 로고    scopus 로고
    • Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors
    • Ongini, E.; Dionisotti, S.; Gessi, S.; Irenius, E.; Fredholm, B.B. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. N.-S. Arch. Pharmacol., 1999, 359, 7-10.
    • (1999) N.-S. Arch. Pharmacol. , vol.359 , pp. 7-10
    • Ongini, E.1    Dionisotti, S.2    Gessi, S.3    Irenius, E.4    Fredholm, B.B.5
  • 221
    • 0042141599 scopus 로고    scopus 로고
    • A2A antagonist prevents dopamine agonist-induced motor complicationsin animal models of Parkinson's disease
    • Bibbiani, F.; Oh, J.D.; Petzer, J.P.; Castagnoli, N.; Chen, J.F.; Schwarzschild, M.A.; Chase, T.N. A2A antagonist prevents dopamine agonist-induced motor complicationsin animal models of Parkinson's disease. Exp. Neurol., 2003, 184, 285-294.
    • (2003) Exp. Neurol. , vol.184 , pp. 285-294
    • Bibbiani, F.1    Oh, J.D.2    Petzer, J.P.3    Castagnoli, N.4    Chen, J.F.5    Schwarzschild, M.A.6    Chase, T.N.7
  • 222
    • 34249034952 scopus 로고    scopus 로고
    • Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: Acute and subchronic studies in rats Eur
    • Tronci, E.; Simola, N.; Borsini, F.; Schintu, N.; Frau, L.; Carminati, P.; Morelli, M. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: Acute and subchronic studies in rats Eur. J. Pharmacol., 2007, 566, 94-102.
    • (2007) J. Pharmacol. , vol.566 , pp. 94-102
    • Tronci, E.1    Simola, N.2    Borsini, F.3    Schintu, N.4    Frau, L.5    Carminati, P.6    Morelli, M.7
  • 223
    • 0022902748 scopus 로고
    • Opioid agonist and antagonist bivalent ligands the relationship between spacer length and selectivity at multiple opioid receptors
    • Portoghese, P.S.; Larson, D.L.; Sayre, L.M.; Yim, C.B.; Ronsisvalle, G.; Tam, S.W.; Talemori, A.E. Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors J. Med. Chem., 1986, 29, 1855-1861.
    • (1986) J. Med. Chem. , vol.29 , pp. 1855-1861
    • Portoghese, P.S.1    Larson, D.L.2    Sayre, L.M.3    Yim, C.B.4    Ronsisvalle, G.5    Tam, S.W.6    Talemori, A.E.7
  • 224
    • 0032474283 scopus 로고    scopus 로고
    • Dimers of 5HT1 ligands preferentially bind to 5HT1B/1D receptor subtypes Bioorg
    • Perez, M.; Jordan-Lebrun, C.; Pauwels, P.J.; Pallard, I.; Halazy, S. Dimers of 5HT1 ligands preferentially bind to 5HT1B/1D receptor subtypes Bioorg. Med. Chem. Lett., 1998, 8, 1407-1412.
    • (1998) Med. Chem. Lett. , vol.8 , pp. 1407-1412
    • Perez, M.1    Jordan-Lebrun, C.2    Pauwels, P.J.3    Pallard, I.4    Halazy, S.5
  • 227
    • 3242794178 scopus 로고    scopus 로고
    • From magic bullets to designed multiple ligands
    • Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today, 2004, 9, 641-651.
    • (2004) Drug Discov. Today , vol.9 , pp. 641-651
    • Morphy, R.1    Kay, C.2    Rankovic, Z.3
  • 228
    • 2542625998 scopus 로고    scopus 로고
    • A bivalent ligand (KDN-21) reveals spinal - and - opioid receptors are organized as heterodimers that give rise to -1 and -2 phenotypes
    • Bhushan, R.G.; Sharma, S.K.; Xie, Z.; Daniels, D.J.; Portoghese, P.S. A bivalent ligand (KDN-21) reveals spinal - and - opioid receptors are organized as heterodimers that give rise to -1 and -2 phenotypes. selective targeting of -heterodimers J. Med. Chem., 2004, 47, 2969-2972.
    • (2004) Selective Targeting of -Heterodimers J. Med. Chem. , vol.47 , pp. 2969-2972
    • Bhushan, R.G.1    Sharma, S.K.2    Xie, Z.3    Daniels, D.J.4    Portoghese, P.S.5
  • 229
    • 0022251438 scopus 로고
    • Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands Evidence for bridging between vicinal opioid receptors
    • Portoghese, P.S.; Larson, D.L.; Yim, C.B.; Sayre, L.M.; Ronsisvalle, G.; Lipkowski, A.W.; Takemori, A.E.; Rice, K.C.; Tam, S.W. Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors J. Med. Chem., 1985, 28, 1140-1141.
    • (1985) J. Med. Chem. , vol.28 , pp. 1140-1141
    • Portoghese, P.S.1    Larson, D.L.2    Yim, C.B.3    Sayre, L.M.4    Ronsisvalle, G.5    Lipkowski, A.W.6    Takemori, A.E.7    Rice, K.C.8    Tam, S.W.9
  • 230
    • 0032531947 scopus 로고    scopus 로고
    • Spanning binding sites on allosteric proteins with polymer-linked ligand dimers
    • Kramer, R.H.; Karpen, J.W. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers Nature, 1998, 395, 710-713.
    • (1998) Nature , vol.395 , pp. 710-713
    • Kramer, R.H.1    Karpen, J.W.2
  • 231
  • 232
    • 15444364860 scopus 로고    scopus 로고
    • A bivalent ligand (KDAN-18) containing -antagonist and -agonist pharmacophores bridges -2 and -1 opioid receptor phenotypes
    • Daniels, D.J.; Kulkarni, A.; Xie, Z.; Bhushan, R.G.; Portoghese, P.S. A Bivalent Ligand (KDAN-18) Containing -Antagonist and -Agonist Pharmacophores Bridges -2 and -1 Opioid Receptor Phenotypes. J. Med. Chem., 2005, 48, 1713-1716.
    • (2005) J. Med. Chem. , vol.48 , pp. 1713-1716
    • Daniels, D.J.1    Kulkarni, A.2    Xie, Z.3    Bhushan, R.G.4    Portoghese, P.S.5
  • 233
    • 44949250688 scopus 로고    scopus 로고
    • Blood-brain barrier permeability considerations for CNS-targeted compound library design
    • Hitchcock, S.A. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr. Opin. Chem. Biol., 2008, 12, 318-323.
    • (2008) Curr. Opin. Chem. Biol. , vol.12 , pp. 318-323
    • Hitchcock, S.A.1
  • 238
    • 51449101712 scopus 로고    scopus 로고
    • Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues
    • Pretorius, J.; Malan, S.F.; Castagnoli, N.; Bergh, J.J.; Petzer, J.P. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg. Med. Chem., 2008, 16, 8676-8684.
    • (2008) Bioorg. Med. Chem. , vol.16 , pp. 8676-8684
    • Pretorius, J.1    Malan, S.F.2    Castagnoli, N.3    Bergh, J.J.4    Petzer, J.P.5
  • 239
    • 84879045217 scopus 로고    scopus 로고
    • Dual targeting of the adenosine a2a receptors and monoamine oxidase b by 4H-3,1-benzothiazin-4-ones
    • Stößel, A.; Hinz, S.; Küppers, P.; Heer, J.; Gütschow, M.; Müller, C.E. Dual Targeting of the Adenosine A2A Receptors and Monoamine Oxidase B by 4H-3,1-Benzothiazin-4-ones. J. Med. Chem., 2013, 56, 4580-4596.
    • (2013) J. Med. Chem. , vol.56 , pp. 4580-4596
    • Stößel, A.1    Hinz, S.2    Küppers, P.3    Heer, J.4    Gütschow, M.5    Müller, C.E.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.